Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Revenue (2023)

Contineum Therapeutics has reported Revenue over the past 1 years, most recently at $50.0 million for Q2 2023.

  • Quarterly results put Revenue at $50.0 million for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was $50.0 million (changed N/A YoY), and the annual figure for FY2023 was $50.0 million, changed.
  • Revenue for Q2 2023 was $50.0 million at Contineum Therapeutics, up from -$92000.0 in the prior quarter.
  • Over the last five years, Revenue for CTNM hit a ceiling of $50.0 million in Q2 2023 and a floor of -$92000.0 in Q1 2023.